Literature DB >> 20104432

Role of progesterone in endometrial cancer.

J Julie Kim1, Eloise Chapman-Davis.   

Abstract

Progesterone is a key hormone in the endometrium that opposes estrogen-driven growth. Insufficient progesterone will result in unopposed estrogen action that could lead to the development of endometrial hyperplasia and adenocarcinoma. Although these endometrial neoplasias can regress in response to progestin treatment, this does not occur in all instances. To understand this resistance to progesterone and to improve on existing hormonal therapies, it is imperative that the molecular mechanisms of progesterone action through its receptor be deciphered in endometrial cancer. This review highlights what is known thus far regarding the efficacy of progestin therapy in the clinic and the role of progesterone in endometrial cancer cell behavior and gene regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20104432      PMCID: PMC4767501          DOI: 10.1055/s-0029-1242998

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  83 in total

Review 1.  Progestin regulation of cellular proliferation.

Authors:  C L Clarke; R L Sutherland
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

Review 2.  Sparing fertility in young patients with endometrial cancer.

Authors:  Luis Chiva; Fernando Lapuente; Lucia González-Cortijo; Natalia Carballo; Juan F García; Alejandro Rojo; Antonio Gonzalez-Martín
Journal:  Gynecol Oncol       Date:  2008-09-18       Impact factor: 5.482

3.  Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2.

Authors:  S Yang; Z Fang; B Gurates; M Tamura; J Miller; K Ferrer; S E Bulun
Journal:  Mol Endocrinol       Date:  2001-12

4.  Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.

Authors:  Anne Beate Vereide; Turid Kaino; Georg Sager; Anne Ørbo
Journal:  Gynecol Oncol       Date:  2005-06       Impact factor: 5.482

5.  Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.

Authors:  Lin Tung; Hany Abdel-Hafiz; Tianjie Shen; Djuana M E Harvell; Lisa K Nitao; Jennifer K Richer; Carol A Sartorius; Glenn S Takimoto; Kathryn B Horwitz
Journal:  Mol Endocrinol       Date:  2006-06-08

6.  Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.

Authors:  R L Arnett-Mansfield; A deFazio; G V Wain; R C Jaworski; K Byth; P A Mote; C L Clarke
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

7.  The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.

Authors:  P H Giangrande; E A Kimbrel; D P Edwards; D P McDonnell
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

8.  Progestin suppresses matrix metalloproteinase production in endometrial cancer.

Authors:  Lisa A Di Nezza; Tom Jobling; Lois A Salamonsen
Journal:  Gynecol Oncol       Date:  2003-05       Impact factor: 5.482

9.  Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors.

Authors:  Donghai Dai; Douglas M Wolf; Elizabeth S Litman; Michael J White; Kimberly K Leslie
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

10.  Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro.

Authors:  M Ueda; H Fujii; K Yoshizawa; F Abe; M Ueki
Journal:  Jpn J Cancer Res       Date:  1996-05
View more
  77 in total

1.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

2.  Interleukin-13 receptor subunit alpha-2 is a target of progesterone receptor and steroid receptor coactivator-1 in the mouse uterus†.

Authors:  Ryan M Marquardt; Kevin Lee; Tae Hoon Kim; Brandon Lee; Francesco J DeMayo; Jae-Wook Jeong
Journal:  Biol Reprod       Date:  2020-10-05       Impact factor: 4.285

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

4.  Mig-6 regulates endometrial genes involved in cell cycle and progesterone signaling.

Authors:  Jung-Yoon Yoo; Tae Hoon Kim; Jae Hee Lee; Sally L Dunwoodie; Bon Jeong Ku; Jae-Wook Jeong
Journal:  Biochem Biophys Res Commun       Date:  2015-05-12       Impact factor: 3.575

5.  Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.

Authors:  Aliyah Almomen; Elke A Jarboe; Mark K Dodson; C Matthew Peterson; Shawn C Owen; Margit M Janát-Amsbury
Journal:  Pharm Res       Date:  2016-05-31       Impact factor: 4.200

6.  Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Authors:  Navdeep Pal; Russell R Broaddus; Diana L Urbauer; Nyla Balakrishnan; Andrea Milbourne; Kathleen M Schmeler; Larissa A Meyer; Pamela T Soliman; Karen H Lu; Pedro T Ramirez; Lois Ramondetta; Diane C Bodurka; Shannon N Westin
Journal:  Obstet Gynecol       Date:  2018-01       Impact factor: 7.661

7.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

Review 8.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

9.  Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.

Authors:  Shunjun Zhao; Genxia Li; Li Yang; Lei Li; Hongyu Li
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

10.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.